Ocular-surface pro-inflammatory antigens

Ocular-surface pro-inflammatory antigens is a collective term for a group of molecular markers and mediators that drive the inflammatory cascade on the ocular surface, particularly in conditions like Dry Eye Disease (DED) and Sjögren's syndrome (3.1.1). The most prominent members of this group include Human Leukocyte Antigen – DR isotype (HLA-DR), an MHC class II molecule, and Intercellular Adhesion Molecule 1 (ICAM-1) (2.1.1, 3.1.1). These antigens are upregulated on conjunctival and corneal epithelial cells in response to environmental stressors or tear film hyperosmolarity, facilitating the recruitment, adhesion, and activation of T-lymphocytes (2.1.1, 3.1.1). This process creates a self-perpetuating cycle of inflammation that leads to ocular surface damage and chronic discomfort (2.1.4, 3.1.2). Therapeutic interventions often target these pathways; for instance, Lifitegrast inhibits the interaction between ICAM-1 and LFA-1, while Cyclosporine reduces the expression of HLA-DR by inhibiting T-cell-mediated cytokine production (2.1.1, 3.1.1). Consequently, these antigens serve as both therapeutic targets and critical biomarkers for diagnosing and monitoring the severity of ocular surface inflammatory disorders (2.1.3, 3.1.1).

Other names

Ocular surface inflammatory markersOcular surface antigensPro-inflammatory mediators of the ocular surfaceConjunctival inflammatory antigens

Drugs targeting these antigens typically work by inhibiting T-cell activation and subsequent cytokine production (e.g., Cyclosporine), blocking the interaction between leukocyte receptors and adhesion molecules like ICAM-1 (e.g., Lifitegrast), or providing broad suppression of the inflammatory cascade (e.g., Corticosteroids).